Talis Biomedical Co. (NASDAQ:TLIS) Short Interest Update

Talis Biomedical Co. (NASDAQ:TLIS) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 21,300 shares, an increase of 52.1% from the July 15th total of 14,000 shares. Based on an average daily volume of 13,900 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.3% of the shares of the stock are short sold.

Institutional Trading of Talis Biomedical

A hedge fund recently bought a new stake in Talis Biomedical stock. BML Capital Management LLC purchased a new position in shares of Talis Biomedical Co. (NASDAQ:TLIS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 42,743 shares of the company’s stock, valued at approximately $318,000. BML Capital Management LLC owned 2.35% of Talis Biomedical at the end of the most recent quarter. 43.77% of the stock is currently owned by institutional investors.

Talis Biomedical Price Performance

NASDAQ TLIS traded up $0.22 during mid-day trading on Friday, hitting $4.36. The stock had a trading volume of 34,794 shares, compared to its average volume of 11,588. The firm’s 50 day moving average is $7.93 and its 200 day moving average is $8.39. Talis Biomedical has a twelve month low of $3.75 and a twelve month high of $9.60. The stock has a market capitalization of $7.94 million, a price-to-earnings ratio of -0.14 and a beta of 1.68.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.